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Distinct implications of different BRCA mutations: 
efficacy of cytotoxic chemotherapy, PARP 
inhibition and clinical outcome in ovarian cancer
Robert L Hollis
Michael Churchman
Charlie Gourley
Nicola Murray Centre for Ovarian 
Cancer Research, Edinburgh Cancer 
Research UK Centre, MRC IGMM, 
Western General Hospital, University 
of Edinburgh, Edinburgh, UK
Abstract: Approximately a fifth of ovarian carcinoma (OC) is associated with inherited germline 
mutations, most commonly in the DNA repair genes BRCA1 or BRCA2 (BRCA). BRCA1- and 
BRCA2-associated OCs have historically been described as a single subgroup of OC that displays 
a distinct set of characteristics termed the “BRCAness” phenotype. The hallmarks of this phe-
notype are superior clinical outcome and hypersensitivity to platinum-based chemotherapy and 
poly-(ADP-ribose) polymerase (PARP) inhibitors. However, growing evidence suggests that 
BRCA1- and BRCA2-associated OCs display distinct characteristics, most notably in long-term 
patient survival. Furthermore, recent data indicate that the site of BRCA1 mutation is impor-
tant with regard to platinum and PARP inhibitor sensitivity. Here, we summarize the body of 
research describing the BRCAness phenotype and highlight the differential implications of 
different BRCA mutations with regard to clinicopathologic features, therapy sensitivity and 
clinical outcome in OC.
Keywords: ovarian cancer, BRCA1, BRCA2, BRCAness
Introduction
Ovarian cancer accounts for ~21% of malignancies diagnosed in the female genital 
tract and is responsible for .14,000 deaths per annum in the US alone.1 More than 
90% of cases are epithelial in origin. Ovarian carcinoma (OC) is now recognized to 
comprise a heterogeneous group of discrete disease entities, each displaying distinct 
clinical behavior and molecular landscapes.2,3 The current standard of care for the 
first-line treatment of OC comprises maximal surgical resection of the tumor mass and 
platinum-based chemotherapy, usually in combination with paclitaxel.4 While some 
therapy stratification based on our understanding of disease biology is beginning to 
emerge in OC – most notably in the advent of poly-(ADP-ribose) polymerase (PARP) 
inhibitor therapy – personalization of OC treatment based on histological subtype and 
molecular characterization remains in its infancy.4,5
Hereditary OC accounts for a significant proportion of cases, with around a fifth 
of patients harboring germline pathogenic sequence variants.6 A large proportion of 
these mutations occur within genes encoding components of the homologous recom-
bination DNA repair (HRR) pathway, most notably in BRCA1 or BRCA2 (BRCA), 
which together account for ~10% of OC cases.7 Other inherited mutations in HRR 
pathway-related genes include BARD1, BRIP1, CHEK2, PALB2 and RAD51C, which 
together account for a minority (#5%) of cases.6
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Historically, BRCA-associated OC has been described 
as a single subtype of OC that displays a distinct set of 
characteristics – frequently referred to as the “BRCAness” 
phenotype.8 However, the differential impact of BRCA1 
versus BRCA2 inactivation has become increasingly 
apparent in recent years.9 Here, we summarize the growing 
body of evidence describing the BRCAness phenotype and 
highlight the emerging evidence of the distinct implications 
of different BRCA mutations on the treatment and clinical 
outcome of OC patients.
Structure and function of BRCA genes
BRCA1
Since its identification in 1994, BRCA1 has become one of 
the most extensively studied tumor suppressor genes to date.10 
BRCA1 comprises 24 exons coding for 1863 amino acids, 
more than half of which are encoded by exon 11.11 Its 208 kDa 
protein product, BRCA1, contains an N-terminal RING 
domain with E3 ligase activity and a phosphoprotein-binding 
C-terminal BRCT domain, encoded by exons 2–7 and 16–24, 
respectively (Figure 1).12–16 Exons 11–13 are known to encode 
a region with two nuclear localization sequences (NLSs) 
and protein-binding domains for a multitude of proteins 
involved in various signaling pathways, including multiple 
tumor suppressors, oncogenes and DNA repair-associated 
proteins.17,18 These include portions of a coiled-coil domain, 
which are known to mediate interactions with PALB2, and 
a serine cluster domain (SCD) whose phosphorylation sites 
are targeted by ATM and ATR kinases in response to DNA 
damage.11,19 Cancer-predisposing BRCA1 mutations are 
known to occur across these three regions, indicating impor-
tant tumor suppressive function in each region.11
BRCA1 is multifunctional, with roles in the DNA dam-
age response, cell cycle checkpoint maintenance and DNA 
repair.20–24 BRCA1 is known to play a role in maintaining the 
G1/S, S-phase and G2/M cell cycle checkpoints; however, 
its principally associated role is in repair of double-stranded 
DNA breaks (DSB), primarily through HRR.20–24 Briefly, 
BRCA1 associates with ubiquitinated histones at DSBs and 
facilitates break resection and subsequent recruitment of 
RAD51 through interaction with PALB2 and BRCA2.25,26 
Accordingly, loss of BRCA1 expression renders cells 
hypersensitive to ionizing radiation and interstrand DNA 
crosslinking agents, consistent with loss of high fidelity 
DSB repair.20,21
BRCA2
BRCA2 comprises 27 exons encoding 3418 amino acids, 
which form its 384 kDa protein product, BRCA2, also 
involved in repair of DSBs through HRR.27,28 BRCA2 exon 11 
contains eight highly conserved BRC repeats that are known 
to interact with RAD51, an essential HRR protein whose 
family members RAD51C and RAD51D have been identified 
as OC susceptibility genes (Figure 1).6,29–33 The C-terminal 
region of BRCA2 also interacts with RAD51 and is known 
to contain two NLS.34
BRCA2 contains a DNA-binding domain compris-
ing an α-helical domain, a tower domain and three 
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Figure 1 Structure of BRCA1 and BRCA2 genes, showing regions encoding identified protein domains, BCCRs and OCCRs.
Abbreviations: BCCR, breast cancer cluster region; OCCR, ovarian cancer cluster region; NLS, nuclear localization sequence; SCD, serine cluster domain; BRCT, BRCA1 
C-terminal domain; OB, oligonucleotide binding.
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oligonucleotide-binding (OB) motifs for binding single- and 
double-stranded DNA (ssDNA and dsDNA).26,35 Pathogenic 
mutations have been detected across the length of BRCA2, 
including in its BRC repeats and DNA-binding domain.9
While BRCA1 is multifunctional, BRCA2 appears to 
function almost exclusively in HRR: it recruits RAD51 to 
DSB sites, a crucial step in repair.28 BRCA2-mutant cells 
are hypersensitive to DNA damage, accumulate gross DNA 
damage with passage in culture and fail to recruit RAD51 to 
DSB sites, but do not appear to demonstrate substantial cell 
cycle checkpoint impairment.36–39
Clinicopathologic features of BRCA-
associated OC
Cancer predisposition in BRCA1 and 
BRCA2 carriers
BRCA mutation carriers are predisposed to a number of 
malignancies, most notably OC and breast cancer (BC). 
However, the level of risk for the development of OC and 
BC appears dependent upon the affected gene.40,41 The average 
cumulative risk of BRCA1 carriers developing BC and OC 
by the age of 70 is ~50%–60% and 40%–50%, respectively, 
while the equivalent risk in BRCA2 carriers is substantially 
lower at ~40%–50% and 10%–20%, receptively.40–42
Growing evidence has begun to elucidate the discrete 
impact of the type and location of BRCA1 and BRCA2 
mutations with regard to cancer predisposition.43–46 These 
studies were founded on the early observation that carriers 
of mutations in the central portion of BRCA1 exon 11 dis-
played an augmented risk of OC versus BC relative to those 
with mutations in other areas of the gene.43,44 Similarly, early 
observations identified increased risk of OC versus BC in 
those harboring mutations in exon 11 of BRCA2 versus muta-
tions in other regions.45
A recent study sought to more thoroughly investigate the 
relationship between BRCA mutation position and differential 
OC versus BC predisposition in an extensive cohort of 
BRCA carriers.46 Analysis of BRCA1 mutation positions 
revealed three regions associated with increased BC versus 
OC risk relative to mutations in other areas of the gene. 
These conferred a relative hazard ratio (HR) of BC versus 
OC (BC-RHR) ranging from 1.34 to 1.46. A cluster region 
within BRCA1 exon 11 conferring increased risk of OC 
versus BC development, relative to other areas of the gene, 
was also identified (BC-RHR =0.62, 95% CI, 0.56–0.70).46 
This is consistent with previous reports of BRCA1 exon 11 
mutations with augmented OC risk.43,44 Such BC cluster 
regions (BCCRs) and OC cluster regions (OCCRs) were also 
identified in BRCA2: multiple BRCA2 BCCRs and OCCRs 
were identified with BC-RHRs ranging from 1.63 to 2.31 
and 0.51 to 0.57, respectively.46
Age at disease onset
As with many cancer predisposition syndromes, BRCA-
linked OC is associated with earlier age at diagnosis.47–49 
Interestingly, BRCA1 carriers appear to develop OC at an 
average of ~7 years earlier versus nonhereditary OC patients, 
while BRCA2 carriers do not display a strong trend for earlier 
diagnosis (Table 1).47,50–53 BRCA1 mutations account for 
over 80% of BRCA-associated OC diagnosed below the age 
of 50, while BRCA2 carriers account for ~60% of BRCA-
associated OC diagnosed at .60 years old, despite the higher 
prevalence of BRCA1 versus BRCA2 mutations in OC.54
Histological subtype of OC
OC is largely grouped into five core histologically defined 
subtypes (histotypes): high-grade serous (HGS), endometri-
oid, clear cell (CC), low-grade serous (LGS) and mucinous 
OC, which together represent over 95% of presenting 
cases.55 HGS OC represents the bulk (~70%) of cases, while 
the endometrioid, CC, LGS and mucinous histotypes are 
reported to account for ~10%, 10%, ,5% and 3% of OC, 
respectively.2,55,56 These histotypes represent inherently 
different tumors, displaying differential chemosensitivity 
and survival, and are now acknowledged to have discrete 
developmental origins.57–62 Indeed, a wealth of evidence now 
illustrates that these represent separate disease entities at both 
the genomic and transcriptomic levels.3,62–65
While a minority of BRCA-mutant CC and endometrioid 
OC have also been identified, BRCA mutations are associated 
predominantly with HGS OC.8,47,66 Germline BRCA mutations 
account for ~15% of HGS OC, with an additional 5%–10% 
displaying somatic BRCA mutations.3,63,67
Metastasis to the viscera
Although the vast majority of OC are diagnosed at advanced 
stage, disease is frequently confined to the peritoneal cavity, 
even at recurrence.68 Even when distant metastases are 
present, the majority involve nonvisceral sites.
BRCA-linked OC has been associated with an increased 
frequency of visceral metastasis, most notably to the liver: 
approximately three in four patients with germline BRCA 
mutations who develop OC display visceral metastasis, 
while the rate in nonhereditary OC patients is estimated at 
less than 20%.69 BRCA1 mutation carriers appear to have a 
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particular propensity to develop visceral metastases: while 
investigations to date have been limited, current data suggest 
that almost all BRCA1 carriers develop disease at visceral 
sites, compared to only around half of BRCA2 carriers.69,70 
Furthermore, BRAC1-associated OC has also been shown to 
display an increased rate of brain metastasis specifically.70
Chemosensitivity
Platinum-based chemotherapy
A predominant characteristic of the BRCAness phenotype is 
their sensitivity to platinum-based DNA-damaging agents, 
even upon repeated exposure at disease recurrence.8,49,71 Tan 
et al8 demonstrated that the majority of BRCA-associated 
OC patients experience partial or complete response to 
platinum-based agents in the second- and third-line settings, 
compared to less than half and less than one-tenth of matched 
controls, respectively. However, they did not compare rates 
in a BRCA1- and BRCA2-mutant gene-specific manner. The 
superior sensitivity of BRCA-associated OC to platinum 
agents was confirmed in later studies of BRCA-associated 
versus nonhereditary OC.49,71
Yang et al53 compared the frequency of primary platinum 
sensitivity of BRCA1 versus BRCA2-associated HGS OC. 
They observed a significantly superior primary platinum 
sensitivity in the BRCA2- versus BRCA1-mutant population: 
100% of BRCA2-associated OC (25 of 25 in their cohort) dis-
played primary platinum sensitivity versus 80% (24 of 30 in 
their cohort) of BRCA1-associated OC.53 They also observed 
a 5.5-month superior platinum-free interval in BRCA2 versus 
BRCA1 carriers and a “mutator phenotype” indicative of high 
genome instability in BRCA2-associated OC.53 Similarly, 
Vencken et al71 reported prolonged treatment-free intervals 
in BRCA2- versus BRCA1-associated OCs, although no sig-
nificantly superior primary response rate was detected.
While investigations are beginning to dissect the dif-
ferential implications of BRCA1 versus BRCA2 mutations 
with regard to chemosensitivity, less is known about the 
implications of the exact mutation site within each of the 
two genes. Recent work has begun to elucidate the distinct 
implication of frameshift-inducing mutations that occur in 
exon 11 of BRCA1.72
In vitro, cells harboring BRCA1 exon 11 frameshifting 
mutations (E11mut) were found to express a BRCA1 isoform 
missing the majority of exon 11 (BRCA1Δ11q). While wild-
type cells and cells harboring mutations outside of exon 11 
(OE11mut) displayed resistance and sensitivity to cisplatin, 
respectively, E11mut cells displayed partial platinum 
resistance.72 E11mut cells were able to form RAD51 and 
Table 1 Characteristics of BRCA1-associated, BRCA2-associated, and BRCA wild-type OC
BRCA1-associated OC BRCA2-associated OC BRCA wild-type OC References
Clinicopathological features
Age at diagnosis Younger versus wT Similar to WT Older versus 
BRCA1-mutant
47–52, 54
Histology Predominantly HGS OC All OC histotypes 8, 47, 66
visceral metastasis Highly likely Likely Unlikely 69, 70
Chemosensitivity
Platinum Highly sensitive
exon 11 and RiNG domain 
mutants may be more resistant
Highly sensitive
May be more sensitive versus 
BRCA1-mutant
Sensitive
Less sensitive versus 
BRCA-mutant
8, 49, 53, 71, 72, 
74, 75
PLD More sensitive versus wT Less sensitive versus 
BRCA-mutant
96, 97
Taxanes May be more resistant 
versus wT
Undetermined May be more sensitive 
versus BRCA1-mutant
82, 84–87, 92, 93
PARP inhibitors Sensitive
exon 11 and RiNG domain 
mutants may be more resistant
Sensitive Resistant versus 
BRCA-mutant
72, 74, 75, 
121–130
Clinical outcome
PFS Superior
May be inferior to BRCA2-mutant
Superior
May be superior to BRCA1-mutant
inferior versus 
BRCA-mutant
53, 71, 144–149
Short-term OS Superior versus WT
inferior versus BRCA2-mutant
Superior versus WT
Superior versus BRCA1-mutant
inferior versus 
BRCA-mutant
53, 66, 143, 147, 
149, 155, 156
Long-term OS
inferior versus BRCA2-mutant
Superior versus WT
Superior versus BRCA1-mutant
inferior versus 
BRCA2-mutant
8, 47, 66, 143, 
147, 149, 155, 156
Abbreviations: BRCA, BRCA1 or BRCA2; OC, ovarian carcinoma; WT, wild-type; HGS, high grade serous; PLD, pegylated liposomal doxorubicin; PFS, progression-free 
survival; OS, overall survival; PARP, poly-(ADP-ribose) polymerase.
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BRCA1 foci in response to ionizing radiation, indicating at 
least partial HRR proficiency. Interestingly, a recent inves-
tigation of OC patients harboring BRCA1 exon 11 mutations 
revealed no significantly superior platinum response rate 
versus the wild-type population.73
While the functional characterization of BRCA1 exon 11 
remains poor, shrouding the mechanisms that underpin the 
partial HRR proficiency of E11mut cells, mutations in better 
characterized portions of the gene have also been correlated 
with chemosensitivity.74,75 Recent investigations suggest that 
while BRCA1 RING domain function appears important for 
tumor suppression, hypomorphic BRCA1 isoforms lacking 
RING domain function display platinum resistance.74,75 
Introduction of the missense brca1C61G mutation into murine 
models demonstrated the poor efficacy of platinum agents 
against brca1C61G breast carcinomas in a study by Drost 
et al.74 They later compared the effects of two BRCA1 trun-
cating mutations, reflecting two known founder mutations in 
the Ashkenazi Jewish population, on chemosensitivity.75–77 
This study demonstrated that introduction of brca1185stop, 
reflective of the BRCA1185delAG founder mutation, led to pro-
duction of a RING-less BRCA1, which mediated resistance 
to cisplatin.75
Together, these data demonstrate a clear differential 
impact for different BRCA mutations. While both BRCA1 
and BRCA2 mutations confer superior sensitivity to 
platinum-based chemotherapy, this phenotype may be exag-
gerated in BRCA2-associated OC. This is perhaps because 
BRCA2-associated OC is rendered HRR defective to a 
greater extent than BRCA1-associated tumors, manifesting 
as extensive genomic instability and exquisite sensitivity to 
DNA damage.53 Furthermore, evidence that not all BRCA1 
mutations are equal is beginning to emerge. Specifically, 
mutations in exon 11 and mutations that abrogate RING 
domain function appear to result in the production of hypo-
morphic BRCA1 isoforms that mediate resistance to platinum 
agents but still predispose carriers to OC development.72–74 
This is consistent with the multifunctional role of BRCA1 
in tumor suppression and suggests that multiple aspects of 
BRCA1 functionality, particularly RING domain function, 
appear dispensable for HRR function.
Taxanes
Taxanes are typically used in combination with platinum 
agents in the treatment of OC but can also be used as single 
agents, usually in the context of platinum resistance.4,78–80 
They are distinct from DNA-damaging agents in their 
mechanism of action, primarily functioning via induction 
of cell cycle arrest at the spindle assembly checkpoint 
through disruption of microtubule disassembly.81 Paclitaxel 
sensitivity may therefore be dependent on intact cell cycle 
checkpoint regulation. Indeed, paclitaxel treatment has been 
shown to induce acute G2/M arrest in the context of BRCA1 
expression.82 Given both the known function of BRCA1 
in cell cycle checkpoint regulation and the suggestion that 
there may be an inverse relationship between paclitaxel and 
cisplatin sensitivity in a range of malignancies, cells may be 
expected to demonstrate paclitaxel resistance in the absence 
of BRCA1 function.23,24,83
A number of in vitro studies have provided evidence 
that BRCA1 may play a role in modulating paclitaxel 
sensitivity.82,84–89 BRCA1-defective BC and head and 
neck squamous cell carcinoma (HNSCC) cells are more 
resistant to paclitaxel treatment versus BRCA1-proficient 
cells, suggesting BRCA1-associated OC may display pacli-
taxel resistance.82,84–87 Additionally, BRCA1 loss appears 
to modulate microtubule dynamics rendering them less 
susceptible to the action of paclitaxel.88 However, some 
in vitro studies have reported conflicting results on the role 
of BRCA1 in modulating taxane sensitivity.90
In line with the notion that BRCA1 deficiency may 
mediate taxane resistance, expression of BRCA1 was associ-
ated with longer time to progression in a taxane-treated cohort 
of BC.91 However, clinical data regarding the sensitivity of 
BRCA-linked OC to taxane monotherapy are severely lim-
ited, with most data described in the context of combination 
with platinum agents. There has been a suggestion that OC 
expressing high BRCA1 mRNA levels may benefit from 
addition of taxanes to platinum, while those with low levels 
do not, though these data are yet to be confirmed in a compre-
hensive cohort of OC.92 It has been shown that BRCA-linked 
OC can benefit from paclitaxel monotherapy in both the 
platinum-sensitive and platinum-resistant relapsed disease 
settings (response rate 60%, 9 of 15 patients and 33%, 3 of 
9 patients, respectively); however, meaningful comparison 
of taxane monotherapy efficacy between BRCA-linked and 
BRCA wild-type OC has not been conducted.93 Critically, 
the existing data have examined BRCA-associated OC as a 
single entity.
While the current data suggest that BRCA1-associated 
OC may be more resistant to paclitaxel, further studies 
are required to investigate this relationship in the clinical 
setting.71 Given the preclinical evidence suggesting that 
BRCA1 mutation specifically may mediate taxane resistance, 
a comprehensive comparison of BRCA-mutant versus BRCA 
wild-type OC in a gene-specific manner, is now needed to 
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elucidate the implication of BRCA status with regard to 
taxane monotherapy. Because BRCA2 appears to function 
almost exclusively in HRR, and the mechanism of action of 
taxanes does not seem to involve induction of DNA damage, 
there is no clear rationale for differential paclitaxel sensitivity 
between BRCA2-associated and BRCA wild-type OC. This 
represents a potential pitfall for therapeutic stratification 
of taxanes while all BRCA-associated OCs continue to be 
considered as a single clinical entity. Future stratification 
within this population specifically will require a wider 
appreciation of the distinction between “BRCA1ness” and 
“BRCA2ness” in clinical practice.
Nonplatinum DNA-damaging agents
Nonplatinum nontaxane chemotherapies are also used in 
the treatment of OC, primarily in the platinum-resistant 
relapsed disease setting.94,95 Pegylated liposomal doxorubicin 
(PLD) represents one such drug whose mechanism of action 
involves DNA damage.
Retrospective studies examining differential response 
rate to PLD have reported superior response and superior 
clinical outcome after PLD treatment in BRCA-associated 
OC versus nonhereditary disease.96,97 Differential sensitivity 
to nonplatinum DNA-damaging agents between BRCA1- 
and BRCA2-mutated OC may be expected to reflect those 
observed for platinum agents; however, these comparisons 
are yet to be made in the context of PLD monotherapy. Simi-
larly, mutations in BRCA1 exon 11 or mutations that affect 
RING domain function may be expected to confer differential 
sensitivity phenotypes versus other BRCA1 mutations.
intraperitoneal chemotherapy 
administration
While the majority of OC treatment is given intravenously 
(IV), chemotherapy may also be administered intraperi-
toneally (IP).4,98,99 IP chemotherapy achieves higher con-
centrations of drug within the peritoneum compared to IV 
administration, delivering dose intense chemotherapy to 
the tumor.99–101
Multiple randomized trials have shown a survival benefit 
for IP administration in advanced-stage OC, particularly in 
the context of optimal surgical debulking.102–106 Although 
uptake of IP administration has increased, IV therapy remains 
the predominant treatment protocol in many centers.107 Cost 
and resource implications for IP administration, as well as 
increased therapy-associated gastrointestinal toxicity, pain, 
and infection among IP-treated patients, have undoubtedly 
contributed to variable uptake of treatment regimens.108 Thus, 
identification of OC subgroups who are likely to benefit most 
from IP administration is an area of keen research interest.
Because BRCA-mutant OC is hypersensitive to platinum 
agents, it is plausible that BRCA status modulates the efficacy 
of this dose intense administration route. This hypothesis has 
in part been explored in the GOG 172 study: this phase III 
trial comparing IP versus IV cisplatin and paclitaxel reported 
greater clinical benefit for OC in the IP arm whose patients 
expressed low levels of BRCA1 protein.109
These data suggest an interaction between BRCA status 
and administration route: the higher concentrations of 
chemotherapy achieved locally during IP treatment may well 
be particularly effective in treating HRR-defective tumors. 
Importantly, these data were limited to immunohistochem-
istry of BRCA1 protein, and we therefore await translational 
analysis of IP-treated OC with matched sequencing data 
for both BRCA1 and BRCA2 in order to fully overlap these 
genomic features with IP chemotherapy outcome. Analysis 
of IP chemotherapy efficacy in BRCA wild-type OC will 
undoubtedly shed light on whether the clinical benefit, if 
any, experienced in this patient group is outweighed by 
excessive toxicity.
Neoadjuvant chemotherapy
Historically, standard OC treatment begins with primary 
debulking surgery (PDS) of the tumor mass followed by 
adjuvant platinum-based or platinum-taxane combination 
chemotherapy.4 However, neoadjuvant chemotherapy (NAC) 
followed by interval debulking surgery (IDS) is increasingly 
used in OC management and is thought to reduce postsur-
gical mortality and morbidities.110,111 Two large trials have 
demonstrated NAC as noninferior to PDS in the treatment 
of advanced stage OC.110,112 However, a recent multi- 
institutional study reported inferior OS in NAC-treated OC 
with stage IIIC disease who achieved optimal primary surgical 
debulking, and there is a clear need to dissect exactly which 
OC patients will benefit most from NAC versus PDS.113
Although there has been no prospective comparison of 
NAC versus PDS in BRCA-associated OC specifically, early 
data are suggesting that BRCA-mutant OC may be associ-
ated with improved response to NAC.114 These findings are 
consistent with the association between BRCA mutation and 
hypersensitivity with platinum.8,49,71
Alarmingly, and in keeping with the concern that NAC 
may promote platinum resistance, the limited data available 
suggest that NAC may provide a selection pressure toward 
BRCA-proficient cells.114 NAC may therefore compromise 
the exquisite platinum sensitivity of BRCA-associated OC 
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by exposing a clonally diverse mass to the selection pressure 
of DNA-damaging agents.115,116 Thus, BRCA carriers may 
benefit most from PDS followed by adjuvant chemotherapy 
directed at residual disease, in the hope that HRR-proficient 
subclones representing a route of chemoresistance may have 
been surgically removed prior to application of a selec-
tion pressure.
Sensitivity to PARP inhibition
Cells harboring BRCA1 or BRCA2 mutation are heavily reli-
ant upon PARP-mediated DNA repair of ssDNA breaks.117 
PARP-inhibited cells are thought to accumulate ssDNA 
damage, which is converted to DSBs during subsequent 
cellular replication, whether through defective ssDNA 
damage repair or PARP trapping at DNA damage sites.117–120 
In the context of HRR deficiency, accumulation of unrepaired 
DSBs results in cytotoxicity and cell death, and BRCA 
mutations therefore exhibit synthetic lethality with PARP 
inhibition.121 Indeed, the PARP inhibitors olaparib, rucaparib 
and niraparib have shown marked antitumor activity in 
monotherapy or maintenance phase II and phase III trials of 
OC patients with particularly marked efficacy demonstrated 
in patients with germline BRCA defects.122–130 Olaparib and 
rucaparib are now licensed by the FDA as a monotherapy 
for recurrent OC in this patient population and olaparib is 
licensed by the European Medicines Agency as a main-
tenance therapy following a response to chemotherapy in 
patients with germline or somatic BRCA mutations.
While both BRCA1 and BRCA2 mutations sensitize 
cells to PARP inhibition, the affected gene appears to have 
a modulating effect on sensitivity: BRCA1-defective cells 
demonstrate ~60-fold increase in sensitivity to olaparib 
versus BRCA wild-type cells, while the corresponding 
increase in sensitivity in BRCA2-defective cells is ~130-
fold.121 However, data regarding differential response rates 
of BRCA1 versus BRCA2 carriers to PARP inhibition in the 
clinical setting are currently limited. Some data suggest a 
trend for slightly superior response rate in BRCA2-associated 
OC treated with PARP inhibitors, while others report no dif-
ference in sensitivity or PFS, and the consensus remains that 
BRCA-associated OC is considered as a single clinical entity 
with regard to PARP inhibitor sensitivity.122–130
While the distinction in sensitivity between BRCA1- 
and BRCA2-associated OCs remains unclear in the clinical 
setting, emerging in vitro data suggest that the location 
of BRCA1 mutation may influence the efficacy of PARP 
inhibitors.72,74,75 Consistent with the notion that the hypo-
morphic BRCA1 isoform BRCA1Δ11q can mediate partial 
HRR function and consequentially platinum resistance, cells 
harboring BRCA1 E11mut cells also appear to display an 
intermediate partially PARP inhibitor-resistance phenotype.72 
Similarly, loss of BRCA1 RING domain function appears 
insufficient to fully sensitize cells to PARP inhibition, while 
still predisposing to cancer development.74,75
Given the financial implications of targeted therapy use 
in routine clinical practice, identifying patients most likely to 
benefit from these drugs is of great importance. Comparison 
of PARP inhibitor sensitivity in patients harboring BRCA1 
exon 11 and RING domain mutations with BRCA wild-type 
patients is warranted to determine whether these patients 
represent a truly HRR-deficient population that benefit from 
PARP inhibition.
BRCA mutations in acquired therapy 
resistance
In recent years, secondary BRCA mutations have been 
implicated in platinum and PARP inhibitor resistance.131 
These mutations restore BRCA function and HRR proficiency 
by restoring open-reading frames, reverting mutant alleles 
back to wild type or removing premature stop codons.132–138 
Such mutations are a known mechanism of cisplatin and 
PARP inhibitor resistance when deriving drug-resistant clones 
in vitro.133–135 In keeping with the notion that these secondary 
events are associated with acquired therapy resistance, 
secondary BRCA2 mutations have been detected in cell lines 
derived from patients subsequent to chemotherapy, and these 
cells are reported to display platinum resistance.133,134,139,140
Mutational analysis of clinical specimens has also revealed 
the presence of secondary BRCA sequence events.132–138 
Secondary mutations have been detected in both BRCA1 
and BRCA2 and correlated with resistance to platinum-based 
chemotherapy.132–135,138 Analysis of BC and OC with acquired 
PARP inhibitor resistance has also uncovered secondary 
BRCA reversion events and demonstrated their potential to 
predict platinum and PARP inhibitor resistance at recurrence 
in BRCA-associated OC.136,137
Clinical outcome
Progression-free survival
Multiple studies have investigated the prognostic significance 
of BRCA mutations on PFS and OS within OC.8,47,53,66,71,141–146 
It has become clear that, together, BRCA-associated disease 
represents a subgroup of OC that experiences superior 
PFS, with studies reporting BRCA-mutant patients expe-
rience PFS around twice that of their BRCA wild-type 
counterparts.71,144–146 Although many studies have failed to 
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analyze PFS in a gene-specific manner, others have sug-
gested that BRCA1-associated OC may experience inferior 
PFS versus BRCA2-associated OC.53,71,147 Indeed, some 
investigators have suggested that BRCA1-associated OC 
may not experience a PFS benefit compared to BRCA wild-
type OC.53,148
A recent meta-analysis of over 18,000 OC patients 
reported superior PFS in both BRCA1- and BRCA2-associated 
OCs.149 They reported HRs for PFS in BRCA1- and BRCA2-
associated versus BRCA wild-type OC of 0.68 (95% CI, 
0.52–0.89) and 0.48 (95% CI, 0.30–0.75), respectively. 
Interestingly, a recent study of BRCA1 exon 11 mutation-
associated OC revealed no PFS benefit versus the wild-type 
population, suggesting an interaction between mutation site 
and PFS.73
Overall survival
A fundamental characteristic of the BRCAness phenotype is 
superior OS.8,47,53,141,146,150–154 Recent work has begun to elucidate 
the distinction between BRCA1 and BRCA2 mutations with 
regard to survival.53,66,143,155 The current consensus is that both 
BRCA1- and BRCA2-mutated OCs experience superior short-
term OS; however, this survival advantage seems exaggerated 
in BRCA2- versus BRCA1-mutant disease.66,143,147,155,156 Five-
year survival in BRCA1- and BRCA2-mutant OC is estimated 
at ~44% and 52%–61%, respectively, versus ~25%–42% in 
BRCA wild-type OC.53,66,143
While BRCA2 carriers continue to experience superior 
long-term OS, the survival of BRCA1-mutant OC patients 
appears limited to ~5 years, with investigators reporting no 
10-year OS advantage in this group.143,155 Hyman et al155 
reported long-term survival benefit in BRCA2-associated 
serous OC versus the BRCA wild-type population, with 
no such benefit in the BRCA1-mutant population. Later, 
Candido-dos-Reis et al143 reported 10-year OS in BRCA1-
associated, BRCA2-associated and BRCA wild-type OC of 
25%, 35% and 30%, respectively, in a large cohort of OC. 
Their study showed an increasingly detrimental effect for 
BRCA1 mutation after ~5 years compared to both BRCA2-
mutated and BRCA wild-type populations.
The recent meta-analysis by Xu et al149 reported HRs 
for OS in BRCA1- and BRCA2-associated versus BRCA 
wild-type OC of 0.73 (95% CI, 0.63–0.86) and 0.57 (95% 
CI, 0.45–0.73), respectively. The study by Dimitrova et al73 
of BRCA1 exon 11-associated OC revealed no 5-year OS 
benefit in this population versus the wild-type population, 
suggesting that all BRCA1 mutations are not equal in convey-
ing survival advantage.
Key future research avenues
Dissecting BRCA1ness from BRCA2ness
A key aim of future research is to continue to dissect the 
distinct phenotypes of BRCA1- and BRCA2-associated 
OCs, both from one another and from BRCA wild-type OC. 
Critically, this will rely on investigators conducting gene-
specific analyses. It is becoming clear that patients with 
BRCA2-associated OC experience an exaggerated BRCAness 
phenotype, displaying superior long-term OS in comparison 
to BRCA1-associated OC, and emerging data suggest that 
superior PFS and platinum sensitivity may also be exagger-
ated in this patient group.53,66,71,143,147,148,155,156
Future studies should aim to elucidate the differential 
sensitivity, if any, of BRCA1- and BRCA2-associated OCs to 
nonplatinum agents, including nonplatinum DNA-damaging 
agents, taxanes and PARP inhibitors. It has been suggested 
that BRCA1-associated OC may be more resistant to pacli-
taxel, and we await data from independent cohorts investi-
gating the potential impact of BRCA1 and BRCA2 mutations 
with regard to taxane monotherapy sensitivity.71,82,84–89,91,92 
While in vitro data suggest that BRCA2-mutant cells are 
more sensitive to PARP inhibition compared to BRCA1-
mutant cells, this comparison is yet to be made in the clini-
cal setting.122–130 Similarly, characterization of how BRCA1 
and BRCA2 mutations may modulate clinical outcome in 
the context of NAC and IP chemotherapy administration is 
now warranted. An appreciation of the distinction between 
BRCA1ness and BRCA2ness by both researchers and 
clinicians will be paramount in the translation of findings 
from these studies into clinical practice.
Correlating mutation site and type to 
chemosensitivity and clinical outcome
While some studies have investigated the impact of BRCA1 
and BRCA2 mutation site on chemosensitivity and OC versus 
BC predisposition, the differential impact of distinct BRCA 
mutation sites remains largely understudied.40–46
Growing data suggest that BRCA1 E11mut cells display 
a distinct partially platinum- and PARP inhibitor-resistant 
phenotype, and OC patients harboring BRCA1 mutations in 
exon 11 may not experience a BRCAness survival benefit.72,73 
Similarly, BRCA1 mutations affecting RING domain func-
tion may also not display hypersensitivity to platinum or 
PARP inhibition.74,75 Further investigation of these findings 
in well clinically annotated OC datasets is now warranted 
to elucidate whether these groups of patients represent a 
non-BRCAness, partially HRR proficient subgroup of OC. 
It may transpire that after removal of these patient groups, 
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the characteristics of the remaining “true” BRCA1-mutant 
HRR-deficient population may be more BRCA2 like.
While some progress has been made investigating 
site-specific implications of BRCA1 mutation, correlation 
of BRCA2 mutation site with platinum sensitivity, PARP 
inhibitor efficacy and survival is yet to be drawn. These 
investigations are likely to be hindered by the relative rarity 
of BRCA2 versus BRCA1 mutation and will require large 
multinational retrospective cohorts of OC. Furthermore, 
while BRCA1 is multifunctional – providing a rationale for 
differential modulation of HRR activity with varying muta-
tion site – BRCA2 appears to function almost exclusively 
in HRR, and phenotypic differences between mutation sites 
may therefore be subtle. Indeed, BRCA2 mutation site may 
not influence chemosensitivity or survival.
Characterizing secondary BRCA 
mutations and their implications for 
treatment failure
Increasingly, research efforts have turned to charac-
terizing mechanisms of acquired chemoresistance in 
BRCA-associated OC. Emergence of disease displaying 
secondary BRCA sequence changes that restore protein 
function has now been demonstrated in both the preclinical 
and clinical settings and has been correlated with therapy 
resistance.132–138 Whether these changes arise de novo or 
through selection of preexisting subclones already pres-
ent at diagnosis remains an area of keen interest and could 
influence the selection of NAC versus PDS. Furthermore, 
investigation into whether different mutation types display 
differential propensity for reversion – and indeed whether 
these correlate with prolonged sensitivity to platinum and 
PARP inhibitors – is yet to be undertaken. Collection of 
temporally and spatially separated biopsies throughout the 
disease journey in BRCA-associated OC will be invaluable 
in correlating acquisition of reversion events with clinical 
outcome, particularly with regard to platinum and PARP 
inhibitor sensitivity. Studies should aim to identify the 
frequency at which clinically relevant secondary BRCA 
mutations arise, the potential therapeutic options to rescue 
resistance in BRCA-reverted patients and whether these 
mutations arise de novo or are present in subclonal popula-
tions at diagnosis.
Conclusion
Clearly, substantial advances in defining the characteristics 
of BRCA-associated OC have been made in the past decade. 
Emerging data are beginning to illuminate the distinction 
between BRCA1- and BRCA2-associated OCs, highlighting 
distinctions between BRCA1ness and BRCA2ness, consis-
tent with the discrete functions of the BRCA1 and BRCA2 
gene products. However, dissecting the characteristics of 
these two distinct OC patient populations from one another 
is an area of ongoing research.
Perhaps most intriguingly, it is becoming clear that not 
all BRCA1 mutations are equal and that mutations at particu-
lar sites – most notably within exon 11 and those affecting 
BRCA1 RING domain function – may not confer a BRCA-
ness phenotype. Instead, their role may be confined to com-
promising the tumor suppressive function of BRCA1, rather 
than inducing HRR deficiency, and thus chemosensitivity. 
We await further clinical data on the implications of muta-
tions at these sites, particularly with regard to sensitivity to 
platinum-based agents and the efficacy of PARP inhibitors. 
Investigation of the impact, if any, of other BRCA1 muta-
tion sites and of different BRCA2 mutations is eagerly 
anticipated.
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